SUMMIT THERAPEU/S (NASDAQ:SMMT) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, reports. The firm currently has a $1.50 price objective on the stock. Zacks Investment Research‘s price target points to a potential upside of 16.28% from the stock’s current price.

According to Zacks, “Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom. “

Several other equities analysts have also weighed in on the stock. ValuEngine raised shares of SUMMIT THERAPEU/S from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. TheStreet raised shares of SUMMIT THERAPEU/S from a “d” rating to a “c-” rating in a research report on Thursday, June 13th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. SUMMIT THERAPEU/S has a consensus rating of “Buy” and an average price target of $2.17.

Shares of SMMT stock traded down $0.11 during trading on Wednesday, hitting $1.29. 1,049 shares of the company were exchanged, compared to its average volume of 47,927. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.93 and a quick ratio of 3.93. The company has a market capitalization of $18.13 million, a price-to-earnings ratio of 1.54 and a beta of 1.22. The business’s 50-day moving average is $1.33. SUMMIT THERAPEU/S has a twelve month low of $1.10 and a twelve month high of $2.59.

SUMMIT THERAPEU/S (NASDAQ:SMMT) last issued its quarterly earnings data on Wednesday, June 12th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.11. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $4.34 million. SUMMIT THERAPEU/S had a net margin of 24.32% and a return on equity of 26.31%. On average, equities analysts predict that SUMMIT THERAPEU/S will post -1.08 earnings per share for the current year.

An institutional investor recently raised its position in SUMMIT THERAPEU/S stock. Bank of New York Mellon Corp grew its position in SUMMIT THERAPEU/S (NASDAQ:SMMT) by 120.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 216,897 shares of the company’s stock after purchasing an additional 118,501 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.57% of SUMMIT THERAPEU/S worth $274,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 18.59% of the company’s stock.


Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Featured Article: Cryptocurrencies

Get a free copy of the Zacks research report on SUMMIT THERAPEU/S (SMMT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with's FREE daily email newsletter.